CDC announces success with PrEP for prevention of HIV in heterosexuals

Current studies in Africa (CDC TDF2 and Partners PrEP) have shown that a daily dose of antiretrovirals can reduce the level of HIV infection amongst those that are currently uninfected. This use of medication by the uninfected is called pre-exposure prophylaxis, or PrEP. The TDF2 study showed a 63% reduction in HIV among those taking Truvada once a day while the Partners PrEP study showed that both the use of Truvada or Viread can significantly reduce HIV transmission among serodiscordant couples.

For more information: Press Release